AI Article Synopsis
- Secukinumab and ixekizumab are IL17A inhibitors used primarily for treating psoriasis, with common side effects including respiratory infections and injection site reactions.
- Recently, these medications have been linked to the development of lichen planus, with similar reactions reported for other biologics like tumor necrosis factor inhibitors.
- A case is presented of a patient who developed lichen planus after starting secukinumab for psoriasis treatment.
Article Abstract
Secukinumab and ixekizumab are IL17A inhibitors most commonly used to treat psoriasis. Common side effects include upper respiratory tract infections, injection site reactions, and mucocutaneous candidiasis. Recently, these medications have been reported to trigger lichen planus and lichenoid reactions have also been reported as an emerging side effect of biologics, especially tumor necrosis factor inhibitors. Herein, we report a patient with lichen planus that appeared after initiation of secukinumab for the treatment of psoriasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5070/D329260779 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical predictors of disease severity in oral lichen planus.
Clin Exp Dermatol
January 2025
Institute of Dentistry, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK.
Background: The limited understanding of factors influencing the disease progression of oral lichen planus (OLP) poses challenges in delivering effective and personalised treatment for this condition, known to increase the risk of oral cancer and adversely impact patient quality of life.
Objective: This study aimed to systematically identify clinical predictors of disease severity in OLP patients.
Methods: This cross-sectional and single-site prospective study was conducted between December 2021 and February 2024 in the Departments of Oral Medicine and Oral & Maxillofacial Surgery, Aberdeen Royal Infirmary.
Death associated protein kinase 1 dampens keratinocyte necroptosis and expression of inflammatory genes in lichen planus.
J Invest Dermatol
December 2024
Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany; Department of Dermatology, Ludwig-Maximilians University Hospital, Munich, Germany. Electronic address:
Lichen planus (LP) is a chronic inflammatory disease (ISD) affecting skin, mucosa, nail, and hair. Previous studies demonstrated a pivotal role of type 1 immunity in LP, as infiltrating T cells trigger apoptosis and necroptosis in the epidermis. In this study, we investigated the role of DAPK1 in LP with special focus on its role in mediating cell death and inflammation.
View Article and Find Full Text PDFLabial Adhesion Surgery Prior to Vaginal Delivery in a Patient With Vulvar Lichen Planus Causing Labial Adhesion: A Case Report.
Cureus
December 2024
Department of Obstetrics and Gynecology, Sendai City Hospital, Sendai, JPN.
Lichen planus is an inflammatory disease that affects the skin and mucous membranes, and although rare, it can manifest in the vulvar region. Vulvar lichen planus can occur in women of reproductive age and may cause vulvar adhesion, potentially complicating examinations and delivery during pregnancy. We report a case in which a pregnant woman with vulvar adhesion due to vulvar lichen planus successfully delivered vaginally following labiaplasty.
View Article and Find Full Text PDFClinicopathological comparison and cytokeratin-10 expression between Lichen planus and oral lichenoid lesions.
Arch Oral Biol
December 2024
Programa de Pós-Graduação em Ciências Odontológicas, Universidade Federal do Espírito Santo (UFES), Brazil. Electronic address:
Objectives: This study aimed to compare clinicopathological features and immunostaining for cytokeratin-10 between oral lichen planus and oral lichenoid lesions.
Design: This was a retrospective longitudinal study comparing lichen planus and oral lichenoid lesions diagnosed at the Oral Pathological Anatomy Service that analyzed sociodemographic and clinicopathological data and CK10 expression. Chi-square tests, Fisher's exact tests and Mann-Whitney tests or Student's t tests were used when appropriate, and p values < 0.
Successful Treatment of Annular Atrophic Lichen Planus With Adalimumab.
Clin Case Rep
January 2025
Department of Geriatric Medicine, Nimes Hospital University Medical Center University of Balamand, Faculty of Medicine and Medical Sciences Balamand Lebanon.
Adalimumab may be an effective treatment for resistant annular atrophic lichen planus, especially in patients with prior treatment failures and contraindications to other systemic therapies. This case underscores the need for exploring systemic options in challenging cases of this rare lichen planus variant.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!